Vacunas最新文献_第10页

Impacto de la vacunación frente a virus del papiloma humano: hacia la eliminación del cáncer de cuello de útero 人乳头瘤病毒疫苗接种对消除子宫颈癌的影响

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-09-10 DOI: 10.1016/j.vacun.2025.500485

Laia Alemany, Maria Brotons

{"title":"Impacto de la vacunación frente a virus del papiloma humano: hacia la eliminación del cáncer de cuello de útero","authors":"Laia Alemany, Maria Brotons","doi":"10.1016/j.vacun.2025.500485","DOIUrl":"10.1016/j.vacun.2025.500485","url":null,"abstract":"<div><div>Certain human papillomavirus (HPV) genotypes are a necessary cause of cervical cancer and are linked to the etiology of a fraction of anogenital and head and neck carcinomas. Currently, twelve HPV types have been classified as definitively carcinogenic by the International Agency for Research on Cancer, of which HPV16 is the most carcinogenic genotype. The carcinogenic classification of HPVs is based on extensive epidemiological studies and biological evidence conducted over the past decades and thanks to the strong collaboration between scientists seeking to uncover the etiology of cervical cancer. HPVs 16, 18, 31, 33, 35, 45, 52, and 58 are responsible for more than 90% of cervical cancers. Since 2006, three effective prophylactic vaccines have been approved in Europe, and have demonstrated to be immunogenic, safe, efficacious and effective. The demonstration of HPV as a necessary cause of cervical cancer has also led to the refinement of screening strategies, such as the introduction of primary HPV testing. Comprehensive cancer research, from etiology to prevention, has had a significant impact on global public health policies, so much so that in 2020 the World Health Organization launched the campaign to eliminate cervical cancer, a possible milestone never before considered in the field of oncology.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 4","pages":"Article 500485"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145160326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retos hacia la eliminación global del sarampión y la rubéola 全球消灭麻疹和风疹的挑战

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-05-12 DOI: 10.1016/j.vacun.2025.500430

Núria Torner

{"title":"Retos hacia la eliminación global del sarampión y la rubéola","authors":"Núria Torner","doi":"10.1016/j.vacun.2025.500430","DOIUrl":"10.1016/j.vacun.2025.500430","url":null,"abstract":"<div><div>Measles and rubella are two vaccine-preventable viral diseases. Vaccination with the measles and rubella containing vaccines (MMR) has significantly reduced the incidence of these diseases, but measles remains a major cause of morbidity and mortality worldwide. Eliminating these diseases requires maintaining high levels of immunity in the population and a comprehensive approach to vaccination programs and primary health care. The WHO has established strategic plans for the elimination of measles and rubella, achieving significant progress in vaccination coverage and reducing cases and deaths. Although vaccination is a highly effective public health intervention, vaccine hesitancy has increased in recent years due to several factors, especially since the COVID-19 pandemic. Pressure from anti-vaccine movements on social media, psychological stress, mental health issues, and a lack of education among health professionals are some of the factors contributing to this hesitancy. To address this problem, which the WHO identified as one of the world's top public health challenges in 2019, a comprehensive and coordinated approach involving all sectors of society is needed to achieve the goal of global elimination.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 4","pages":"Article 500430"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145160320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

C0047 PARTICIPACIÓN DE LA FARMACIA COMUNITARIA EN LOS PLANES DE VACUNACIÓN EN ESPAÑA C0047社区药房参与西班牙的疫苗接种计划

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500537

Raquel Varas Doval , Jordi de Dalmases , Antonio Blanes , Juan Ignacio Alfaro , Esteban Lifschitz

引用次数: 0

C0040 PERFIL DE LOS VIAJEROS QUE REQUIEREN VACUNACIÓN PREEXPOSICIÓN ANTIRÁBICA C0040需要进行接触前疫苗接种的旅行者简介

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500532

Rosa M. Sancho Martínez

引用次数: 0

C0060 HERPES ZÓSTER: ANÁLISIS DE LOS EPISODIOS HOSPITALARIOS EN 2022-2023 Y SU ANTECEDENTE VACUNAL EN LA COMUNIDAD DE MADRID C0060带状疱疹：2022-2023年住院病例分析及其在马德里市的疫苗病史

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500542

Paula Navarro López , Amaya Sánchez Gómez , María Ángeles Gutiérrez Rodríguez , Gema María Vicente Sánchez , María C. Vázquez Torres , Marta Molina Olivas

引用次数: 0

C0055 IMPLEMENTACIÓN DE UN NUEVO SISTEMA DE REGISTRO CON DATAMATRIX C0055采用新的数据录入系统

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500539

Jesus Javier Yelo Cano, Mari Cruz Gómez Moreno, Consuelo Lucía Álvarez García, Lidia José Riquelme Valverde, Susana Sánchez Manresa, Matilde Zornoza Moreno

引用次数: 0

C0064 VACUNAS INNOVADORAS Y TERAPIAS INMUNOLÓGICAS: NUEVAS REACCIONES ADVERSAS QUE LOS CLÍNICOS DEBEN CONOCER Y CÓMO ACTUAR ANTE ELLAS C0064创新疫苗和免疫疗法：临床医生应了解的新出现的危险反应以及如何应对这些反应

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500545

Itsaso Arribas, Daniel Cózar, Iva Kamenova, Xavier Marfà

引用次数: 0

C0156 INEQUIDADES EN LA INMUNIZACIÓN FRENTE A VRS CON NIRSEVIMAB SEGÚN VARIABLES SOCIODEMOGRÁFICAS POR SECCIONES CENSALES EN UNA CIUDAD ESPAÑOLA C0156西班牙城市中按人口中心分列的不同社会和人口特征造成的针对奈瑟维玛布的免疫不公正现象

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500603

Fernando Lamas Hermoso , Daniel Castrillejo Pérez , Atanasio Gómez Anés , Joaquín Lamas Mille , José Ruiz Olivares , Luisa Fernanda Hermoso Castro

引用次数: 0

C0063 PACIENTES EN TRATAMIENTO ANTI-CD20: IMPORTANCIA DEL MOMENTO DE VACUNACIÓN C0063接受CD20治疗的患者：疫苗接种时间的重要性

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500544

Lucía Sánchez Piorno, Sandra Ferro Larroy, Paz Rodríguez Cundín, Carmen Martín Noda, Angélica Higuera Moreno, Leticia Cortes Salan, Lucía Quintilla Martínez, Henar Rebollo Rodrigo

引用次数: 0

C0126 IMPACTO DE INMUNIZACIÓN FRENTE A VRS EN PACIENTES DE NUESTRO ENTORNO SANITARIO. C0126免疫对我们卫生环境中的病人的影响。

Vacunas Pub Date : 2025-10-01 Epub Date: 2025-11-10 DOI: 10.1016/j.vacun.2025.500581

Carmen Medina Bailón , Emely Garcia Carrasco , Benjamin Muedra , Aitana Morano Vázquez , Marta Grande Arnesto , Nieves Lopez Fresneña

引用次数: 0